{"protocolSection":{"identificationModule":{"nctId":"NCT01910363","orgStudyIdInfo":{"id":"A1A2BONT"},"secondaryIdInfos":[{"id":"TU001","type":"OTHER_GRANT","domain":"Tokushima University"}],"organization":{"fullName":"University of Tokushima","class":"OTHER"},"briefTitle":"Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke","officialTitle":"Comparison of Clinical Efficacy of Botulinum Neurotoxin Type A1 and A2 for Post-Stroke Lower Limb Spasticity: Phase 2/3","acronym":"A2NTX"},"statusModule":{"statusVerifiedDate":"2014-01","overallStatus":"UNKNOWN","lastKnownStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-07"},"primaryCompletionDateStruct":{"date":"2014-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2013-07-18","studyFirstSubmitQcDate":"2013-07-26","studyFirstPostDateStruct":{"date":"2013-07-29","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-01-09","lastUpdatePostDateStruct":{"date":"2014-01-10","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ryuji Kaji","investigatorTitle":"Professor and Chairman, Department of Neurology","investigatorAffiliation":"University of Tokushima"},"leadSponsor":{"name":"University of Tokushima","class":"OTHER"},"collaborators":[{"name":"Ministry of Health, Labour and Welfare, Japan","class":"OTHER_GOV"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To test the safety and efficacy of a new generation botulinum toxin preparation A2NTX for treating stroke patients with lower limb spasticity.\n\n* we study the degree of spasticity in the ankle and knee joints, and walking speed in 30 patients with stroke before and after injecting 300 units of BOTOX or A2NTX in a blinded manner as for the patient, the physician, and the examiner.\n* we also assess the safety of A2NTX and compare it to that of BOTOX."},"conditionsModule":{"conditions":["Lower Limb Spasticity After Stroke"],"keywords":["poststroke spasticity","lower limb","botulinum toxin","A2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"A2NTX","type":"EXPERIMENTAL","description":"single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2","interventionNames":["Drug: A2NTX"]},{"label":"BOTOX","type":"ACTIVE_COMPARATOR","description":"single intramuscular injection of 300 units of BOTOX®, a commercially available botulinum toxin preparation of type A1","interventionNames":["Drug: BOTOX"]}],"interventions":[{"type":"DRUG","name":"A2NTX","description":"Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.","armGroupLabels":["A2NTX"],"otherNames":["A2NTX:low molecular weight (150kDalton) purified botulinum toxin type A2 preparation"]},{"type":"DRUG","name":"BOTOX","description":"Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.","armGroupLabels":["BOTOX"],"otherNames":["BOTOX®:onabotulinumtoxinA (Allergan Co Ltd), commercially available botulinum toxin type A1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Modified Ashworth Scale of the ankle joint","description":"Modified Ashworth Scale is measured at baseline, 30(27-33) days and 60 (56-63) days after injection. Area under curve of Modified Ashworth Scale changes at day 30 and day 60 after injection","timeFrame":"30-60 days after injection"}],"secondaryOutcomes":[{"measure":"Change in Functional Independence Measure (FIM)","timeFrame":"30 days after injection"}],"otherOutcomes":[{"measure":"Walking Speed for 3m","description":"Time required for a patient to stand up from sitting position in a chair of 50cm height and walk for 3m.\n\nIf assistance is needed, the same method of assisting the patient is used throughout the study.","timeFrame":"30 days after injection"},{"measure":"grasp power","description":"Grasping power of both upper limbs will be measure with a standard grasp measure device in kg units. Because injection is made into lower limbs, any decrease of grasp power will be assessed as the measure of unwanted spread of the toxin action.","timeFrame":"30 days after injection"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients with lower limb spasticity after stroke\n* duration more than 6 months\n* Modified Ashworth Scale of ankle joint more than 2\n\nExclusion Criteria:\n\n* patients with previous botulinum toxin injections to lower limbs\n* patients with serious hepatic, renal or cardiac dysfunction\n* patients with respiratory failure\n* patients who cannot understand the instructions","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Tokushima University Hospital","city":"Tokushima","zip":"770-8503","country":"Japan","geoPoint":{"lat":34.06667,"lon":134.56667}}]},"referencesModule":{"references":[{"pmid":"26394198","type":"DERIVED","citation":"Kaji R. Clinical differences between A1 and A2 botulinum toxin subtypes. Toxicon. 2015 Dec 1;107(Pt A):85-8. doi: 10.1016/j.toxicon.2015.09.025. Epub 2015 Sep 21."}]}},"annotationSection":{"annotationModule":{"unpostedAnnotation":{"unpostedResponsibleParty":"Ryuji Kaji, Professor and Chairman, Department of Neurology, University of Tokushima","unpostedEvents":[{"type":"RELEASE","date":"2017-11-18"},{"type":"UNRELEASE","date":"2018-05-24"},{"type":"RELEASE","date":"2018-05-24"},{"type":"RESET","date":"2018-12-14"},{"type":"RELEASE","date":"2021-10-06"},{"type":"RESET","date":"2021-11-04"},{"type":"RELEASE","date":"2022-04-25"},{"type":"RESET","date":"2023-01-26"}]}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"estimatedResultsFirstSubmitDate":"2017-11-18","submissionInfos":[{"releaseDate":"2017-11-18","unreleaseDate":"2018-05-24"},{"releaseDate":"2018-05-24","resetDate":"2018-12-14"},{"releaseDate":"2021-10-06","resetDate":"2021-11-04"},{"releaseDate":"2022-04-25","resetDate":"2023-01-26"}]}},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Previous","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}